Cumberland Pharma (CPIX) Announces Launch of Ethyol Promotion in U.S.
- Wall Street dips as telecoms slump; AmEx surges
- Microsoft (MSFT) Tops Q1 EPS by 8c
- AMD (AMD) Posts Q3 Operating EPS of 3c; Sees Q4 Revenue Down Sequentially
- AT&T (T) Said to Discuss Idea of Takeover in Time Warner (TWX) Meetings
- Alkermes plc (ALKS) Announces Third ALKS 5461 Phase 3 Met Primary Endpoint in MDD
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) announced that it has launched the U.S. promotion of Ethyol (amifostine) for Injection, a hospital-based product used to treat oncology patients. Ethyol is an FDA approved cytoprotective drug indicated to reduce the incidence of xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer. It also reduces the cumulative renal toxicity associated with the repeated administration of cisplatin in patients with advanced ovarian cancer. Cumberland entered into an exclusive agreement with Clinigen Group plc to commercialize Ethyol in the United States earlier this year. Cumberland is responsible for all distribution, promotion, and medical support of Ethyol in the United States.
"We are pleased to now offer Ethyol to oncology patients throughout the United States," said A.J. Kazimi, Chief Executive Officer of Cumberland Pharmaceuticals. "We have worked diligently to prepare for the reintroduction of Ethyol and are excited to expand our activities into hospital-based oncology and this new patient population."
In preparation for the product's launch, Cumberland completed training its sales and medical organization, stocked the product at wholesalers serving hospitals nationwide, and recently introduced the product website. Ethyol will be supported by Cumberland's hospital sales force. Ethyol is Cumberland's first oncology support product and complements its current portfolio of specialty hospital pharmaceuticals.
Ethyol is a key global brand within the Specialty Pharmaceuticals division of Clinigen Group and is the first product that Cumberland has licensed from Clinigen under an exclusive strategic alliance entered into in 2015. The U.S. launch represents an important milestone in ensuring patients have the best opportunity to be treated with Ethyol, should they need it.
"The U.S. launch of Ethyol represents a major step forward in Clinigen Group's mission of ensuring patients worldwide have access to the medicines they need," said Shaun Chilton, Deputy Chief Executive Officer of Clinigen Group. "Patients in the U.S. are now able to access Ethyol to manage the side effects of their vital cancer treatment. Our strategic alliance with Cumberland is a key part of our global revitalization strategy for Ethyol, an important treatment for cancer patients."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Independent Bank (INDB), Island Bancorp Enter Merger Agreement
- Omeros (OMER) Announces Positive OMS721 Phase 2 Data in HSCT-TMA; TMA Markers Improved Over Time
- Penn National Gaming (PENN) Appoints New CFO
Create E-mail Alert Related CategoriesCorporate News, Management Comments
Related EntitiesDefinitive Agreement
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!